Leon Neal
- ViiV Healthcare, which is majority owned by GSK (NYSE:GSK), said it will expand a licensing agreement with the Medicines Patent Pool that will allow manufacturers to produce generic Apretude (cabotegravir) for low-income countries as a long-acting HIV treatment.
- Previously, the agreement